News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Global Pancreatic Cancer Treatment Market Value To More Than Treble By 2017, Says Globaldata


4/1/2014 9:33:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LONDON, UK (GlobalData), 1 April 2014 - The global pancreatic cancer treatment market value in the six major countries (6MM: the US, France, Germany, Italy, Spain and the UK) will increase significantly from $529 million in 2012 to $1.63 billion by 2017, at an impressive Compound Annual Growth Rate (CAGR) of 25.2%, says a new report from research and consulting firm GlobalData.

According to the company’s report*, the US will show the most growth in the pancreatic cancer therapeutics market, with its total value jumping from $275 million in 2012 to $1.17 billion by 2017, at a higher CAGR of 33.5%. The US will be followed by the five European countries, with their combined market values expected to increase from $254 million in 2012 to $463 million by 2017, at a CAGR of 12.8%.

Savade Solanki, Ph.D., GlobalData’s Associate Director of Oncology, says that this rapid market expansion is due to the launch of Celgene’s Abraxane in the US and Europe in 2013 and 2014, respectively, along with the incorporation of five pipeline agents into US clinical practice.

“Out of the five upcoming pipeline agents, NewLink Genetics Corporation’s algenpantucel-L is expected to garner the highest sales and will be launched in both resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck’s TH-302 and Merrimack Pharmaceuticals’ MM-398,” Solanki says.

GlobalData expects Abraxane’s sales to undergo a massive rise, from $21 million (off-label) in 2012 to $954 million in 2017, at a CAGR of 115%. Abraxane will represent nearly 60% of the pancreatic cancer therapeutics market by the end of the forecast period.

Solanki concludes: “The large number of unmet needs in this disease, coupled with high physician familiarity, have facilitated the rapid adoption of Abraxane into clinical practice for advanced pancreatic cancer. We expect the Abraxane-gemcitabine regimen to win substantial patient share from all other major treatment options, including gemcitabine monotherapy, Tarceva-gemcitabine, and FOLFIRINOX regimens.”

*OpportunityAnalyzer: Pancreatic Cancer Opportunity Analysis and Forecasts to 2017

This report provides analysis on the pancreatic cancer therapeutics market revenue from 2012 to 2017, including annual cost of therapy, and major marketed and pipeline drug sales during the forecast period.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx

-ABOUT GLOBALDATA-

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES